WASHINGTON--(BUSINESS WIRE)--The Alliance for Biosecurity and MD Becker Partners today announced the release of a joint industry report titled, "Medical Countermeasures: A Roundtable Discussion."
"Companies working to develop and manufacture medicines and vaccines to protect the public from health emergencies, which are collectively referred to as medical countermeasures, face some inherent, but surmountable, challenges," said Maureen Hardwick, Executive Secretary of the Alliance for Biosecurity. “For over a decade these companies have partnered with the U.S. government and there are now more than 70 medical countermeasures in late stage development and several new life-saving products in the Strategic National Stockpile ready for use in an emergency.”
The Alliance for Biosecurity and MD Becker Partners organized this roundtable discussion to provide valuable information about the field from key opinion leaders, analysts, and industry executives. In total, a panel of 16 experts participated, sharing their reflections on important advancements, lessons learned, core challenges and recommendations for the future of the medical countermeasures enterprise.
"Even in an environment of limited commercial market and regulatory challenges, there are opportunities," said Michael Becker, Founder and Senior Partner at MD Becker Partners. "For example, biodefense companies have recognized that the expertise and knowledge gained by developing and manufacturing medical countermeasures can greatly benefit a company as they advance other commercial drug candidates."
The experts concluded that there is a need for strengthened leadership, long term funding, increased transparency, and streamlined contracting in the medical countermeasure enterprise.
A complimentary copy of the full report can be obtained using the following website link: http://mdbpartners.com/medical-countermeasures-report
Roundtable experts participating in the report include:
- Daniel Abdun-Nabi, Emergent BioSolutions Inc.
- U.S. Senator Richard Burr (NC)
- Nathan Cali, B.S., M.B.A., Noble Financial Capital Markets
- John Grabenstein, Ph.D., COL, USA (Ret.), Merck & Co., Inc.
- James Greenwood, Biotechnology Industry Organization (BIO)
- Margaret Hamburg, M.D., U.S. Food and Drug Administration
- Anders Hedegaard, Bavarian Nordic A/S
- Robert Kadlec, M.D.
- Michael Novod, Nordea Bank
- Elizabeth Posillico, Ph.D., Elusys Therapeutics, Inc.
- Eric Richman, PharmAthene, Inc.
- U.S. Congressman Mike Rogers (MI)
- Eric Rose, M.D., SIGA Technologies
- Bruce Ruscio, Novartis Vaccines and Diagnostics
- Raghuram Selvaraju, Ph.D. MBA, Aegis Capital Corp.
- Craig Vanderwagen, M.D., RADM, USPHS, Martin, Blanck & Associates
About the Alliance for Biosecurity
The Alliance for Biosecurity is a collaboration among pharmaceutical and biotechnology companies that are working in the public interest to improve prevention and treatment of severe infectious diseases—particularly those diseases that present global security challenges. The Alliance for Biosecurity promotes a stronger, more effective partnership between government, the biopharmaceutical industry, and other stakeholders in order to advance their shared goal of developing critically needed medical countermeasures. For more information, visit the Alliance for Biosecurity website at www.allianceforbiosecurity.org.
About MD Becker Partners
MD Becker Partners is a boutique management and strategy consulting firm focusing on both public and private companies in the life sciences industry. The firm also works with venture capitalists, institutional investors, and others that provide capital to these companies. As a strategic advisor and partner, MD Becker Partners provides a full range of services to help its clients increase visibility, unlock stakeholder value, and access resources to grow their business. To accomplish this, the firm integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. For more information, visit the firm's website at www.mdbpartners.com and online newsletter at www.lifesciencedigest.com.